Numerous clinical trials, primarily utilizing immunomodulatory Lactobacillus and Bifidobacterium strains, were subsequently undertaken to assess their efficacy against COVID-19 (483)
GLP-1 RA medications are making headlines again, this time for success in a large-scale clinical trial focusing on a new health target: cardiovascular disease
Research assessing muscle and tendon healing reported increases in angiogenic markers such as VEGF, CD34, and factor VIII in injured tissue following peptide exposure [6]
100 WangL.ZhangR.HouX.WangC.GuoS.NingN.et al (2019)
They work by increasing insulin secretion, decreasing appetite, and slowing gastric emptying
The studies were categorized into four groups: inflammatory pain and osteoarthritis, headaches, neuropathic pain and diabetic neuropathy, and visceral pain and irritable bowel syndrome